Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Panel B shows the patient at the initial T-cell lymphoma (TCL) presentation before biopsy. Panel C shows anticamelid staining (which detects the llama-derived CAR) of the lymph-node biopsy sample ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a study published in the Journal of Clinical Investigation.

Patients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...

has made a major breakthrough in treating a common and challenging form of cancer called diffuse large B-cell lymphoma (DLBCL). In a clinical trial known as EPCORE NHL-2, the researchers showed ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...